Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan for exercise capacity in Eisenmenger syndrome
NL-OMON41378Phase 3Withdrawn
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Eisenmenger syndrome and pulmonary arterial hypertension (PAH) comparing Macitentan with Placebo (2 arms). Primary endpoint: Exercise capacity. Planned start Feb 2013; status: withdrawn.
02
Drugs
macitentan
03
Conditions
Eisenmenger syndromepulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON41378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41378.